 |
|
|
| |
No Meaningful Pharmacokinetic Interaction Between Hepatitis C Virus Protease Inhibitor MK-5172 and Ethinyl Estradiol and Levonorgestrel
|
| |
| |
Reported by Jules Levin
Presented at HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis, December 8-12, 2013, Big Island, Hawaii
WW Yeh1, CB Smith1, L Caro1, J Talaty1, Z Guo1, TE O'Reilly2, and JR Butterton1
1Merck & Co., Inc., Whitehouse Station NJ, USA, 2Celerion, Phoenix, AZ, USA
|
| |
|
|
|
|
|
